

# Financial Tear Sheet

## Corporate Profile

BrainStorm (NASDAQ:BCLI) is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson's Disease (PD).

## Stock Information

BCLI (Common Stock)	
Exchange	NASDAQ CM (US Dollar)
Price	\$4.02
Change (%)	▼ 0.02 (0.50%)
Volume	20,571
52 Week Low	\$2.06
Market Cap	\$75,316,911
Rolling EPS	-0.27
PE Ratio	0
Shares Outstanding	18,735,550
Data as of 05/26/17 4:00 p.m. ET	



Data provided by Nasdaq. Minimum 15 minutes delayed.

## Latest News

May 22, 2017

**BRAINSTORM TO PRESENT AT CELL & GENE EXCHANGE CONFERENCE IN WASHINGTON DC**

May 16, 2017

**BRAINSTORM INITIATED TECHNOLOGY TRANSFER TO CITY OF HOPE FOR U.S. PRODUCTION OF NUROWN® FOR PHASE 3 ALS STUDY**

May 15, 2017

**BRAINSTORM ANNOUNCES FIRST QUARTER 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE**

## SEC Filings

Filing Date	Form
05/15/17	10-Q
03/29/17	10-K
03/06/17	8-K
03/06/17	4

## Upcoming Events

**WORLD ADVANCED THERAPIES & REGENERATIVE MEDICINE CONGRESS 2017**

May 18, 2017 2:40 p.m. CT

**INTERNATIONAL SOCIETY FOR CELLULAR THERAPY ANNUAL CONFERENCE**

May 4, 2017 3:30 p.m. CT

**INTERNATIONAL SOCIETY FOR CELLULAR THERAPY ANNUAL CONFERENCE**

May 4, 2017 5:00 p.m. CT

## Primary IR Contact

Michael Rice

LifeSci Advisors LLC

E-mail: [mrice@lifesciadvisors.com](mailto:mrice@lifesciadvisors.com)